Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
OCGN Ocugen Inc
- Stocks
- Healthcare
- NASDAQ: OCGN
Price (delayed)
$1.09
Market cap
$318.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.19
Enterprise value
$312.03M
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier
Highlights
The EPS has grown by 21% year-on-year and by 5% since the previous quarter
The debt has contracted by 2.1% from the previous quarter
OCGN's quick ratio is up by 38% year-on-year but it is down by 17% since the previous quarter
OCGN's revenue is down by 32% YoY but it is up by 12% from the previous quarter
The equity fell by 47% YoY and by 46% QoQ
The net income fell by 6% QoQ
Key stats
What are the main financial stats of OCGN
Market
Valuations
Earnings
Shares outstanding
292.03M
Market cap
$318.31M
Enterprise value
$312.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
20
Price to sales (P/S)
70.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69
Revenue
$4.52M
Gross profit
$4.52M
Operating income
-$57.04M
Net income
-$57.48M
EBIT
-$56.57M
EBITDA
-$52.86M
Free cash flow
-$51.95M
Per share
Balance sheet
Liquidity
EPS
-$0.19
EPS diluted
-$0.19
Free cash flow per share
-$0.18
Book value per share
$0.05
Revenue per share
$0.02
TBVPS
$0.22
Total assets
$64.46M
Total liabilities
$48.55M
Debt
$31.82M
Equity
$15.91M
Working capital
$27.08M
Debt to equity
2
Current ratio
2.6
Quick ratio
2.26
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
-1,168.9%
Gross margin
100%
Net margin
-1,271.2%
Operating margin
-1,261.4%
Return on assets
-84.2%
Return on equity
-203.7%
Return on invested capital
-219.2%
Return on capital employed
-118.9%
Return on sales
-1,251%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCGN stock price
How has the Ocugen stock price performed over time
Intraday
2.83%
1 week
30.2%
1 month
62.69%
1 year
-31.88%
YTD
35.4%
QTD
54.33%
Financial performance
How have Ocugen's revenue and profit performed over time
Revenue
$4.52M
Gross profit
$4.52M
Operating income
-$57.04M
Net income
-$57.48M
Gross margin
100%
Net margin
-1,271.2%
The net margin has contracted by 46% YoY but it has grown by 4.6% from the previous quarter
The company's operating margin fell by 40% YoY but it rose by 7% QoQ
OCGN's revenue is down by 32% YoY but it is up by 12% from the previous quarter
Ocugen's gross profit has decreased by 32% YoY but it has increased by 12% QoQ
Price vs fundamentals
How does OCGN's price correlate with its fundamentals
Growth
What is Ocugen's growth rate over time
Valuation
What is Ocugen stock price valuation
P/E
N/A
P/B
20
P/S
70.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69
The EPS has grown by 21% year-on-year and by 5% since the previous quarter
The price to book (P/B) is 130% more than the 5-year quarterly average of 8.7 and 55% more than the last 4 quarters average of 12.9
The equity fell by 47% YoY and by 46% QoQ
The price to sales (P/S) is 32% more than the last 4 quarters average of 53.3
OCGN's revenue is down by 32% YoY but it is up by 12% from the previous quarter
Efficiency
How efficient is Ocugen business performance
OCGN's ROE has dropped by 76% year-on-year and by 11% since the previous quarter
The ROIC has grown by 44% YoY and by 21% from the previous quarter
The return on sales has declined by 43% year-on-year but it has grown by 6% since the previous quarter
The return on assets has grown by 8% since the previous quarter but it has declined by 2.2% year-on-year
Dividends
What is OCGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCGN.
Financial health
How did Ocugen financials performed over time
OCGN's total assets is 33% greater than its total liabilities
The company's total liabilities has surged by 125% YoY but it fell by 8% QoQ
The current ratio is up by 39% year-on-year but it has declined by 9% since the previous quarter
The debt is 100% more than the equity
The debt to equity has surged by 82% since the previous quarter
The equity fell by 47% YoY and by 46% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.